Home LiteratureArticle Details
PMID: 17074082 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

BMC genomics ·Vol. 7 ·2006-10-30 ·Pages 278

Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ

Abstract

A 70-gene tumor expression profile was established as a powerful predictor of disease outcome in young breast cancer patients. This profile, however, was generated on microarrays containing 25,000 60-mer oligonucleotides that are not designed for processing of many samples on a routine basis. To facilitate its use in a diagnostic setting, the 70-gene prognosis profile was translated into a customized microarray (MammaPrint) containing a reduced set of 1,900 probes suitable for high throughput processing. RNA of 162 patient samples from two previous studies was subjected to hybridization to this custom array to validate the prognostic value. Classification results obtained from the original analysis were then compared to those generated using the algorithms based on the custom microarray and showed an extremely high correlation of prognosis prediction between the original data and those generated using the custom mini-array (p < 0.0001). In this report we demonstrate for the first time that microarray technology can be used as a reliable diagnostic tool. The data clearly demonstrate the reproducibility and robustness of the small custom-made microarray. The array is therefore an excellent tool to predict outcome of disease in breast cancer patients.

MeSH Terms
Biomarkers, Tumor/genetics Breast Neoplasms/diagnosis,genetics Female Gene Expression Profiling/methods Humans Kaplan-Meier Estimate Middle Aged Oligonucleotide Array Sequence Analysis/methods Prognosis Reproducibility of Results Sensitivity and Specificity
Chemicals
Biomarkers, Tumor
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Glas Annuska M
Agendia BV, Slotervaart Medical Center 9D, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. annuska.glas@agendia.com
Floore Arno
Delahaye Leonie J M J
Witteveen Anke T
Pover Rob C F
Bakx Niels
Lahti-Domenici Jaana S T
Bruinsma Tako J
Warmoes Marc O
Bernards René
Wessels Lodewyk F A
Van't Veer Laura J
References (25)
25 references, click to expand
  1. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.
    Blood. 2005 Jan 1;105(1):301-7 PMID: 15345589
  2. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
    Science. 1999 Oct 15;286(5439):531-7 PMID: 10521349
  3. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  4. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
    J Clin Oncol. 2005 May 20;23(15):3331-42 PMID: 15908647
  5. Rosetta error model for gene expression analysis.
    Bioinformatics. 2006 May 1;22(9):1111-21 PMID: 16522673
  6. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
    J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92 PMID: 16954471
  7. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
    Nature. 2000 Feb 3;403(6769):503-11 PMID: 10676951
  8. Functional discovery via a compendium of expression profiles.
    Cell. 2000 Jul 7;102(1):109-26 PMID: 10929718
  9. Molecular classification of cutaneous malignant melanoma by gene expression profiling.
    Nature. 2000 Aug 3;406(6795):536-40 PMID: 10952317
  10. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  11. Gene-expression profiles in hereditary breast cancer.
    N Engl J Med. 2001 Feb 22;344(8):539-48 PMID: 11207349
  12. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.
    Nat Med. 2001 Jun;7(6):673-9 PMID: 11385503
  13. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  14. Multiclass cancer diagnosis using tumor gene expression signatures.
    Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 PMID: 11742071
  15. Prediction of central nervous system embryonal tumour outcome based on gene expression.
    Nature. 2002 Jan 24;415(6870):436-42 PMID: 11807556
  16. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  17. Use of hybridization kinetics for differentiating specific from non-specific binding to oligonucleotide microarrays.
    Nucleic Acids Res. 2002 Aug 15;30(16):e86 PMID: 12177314
  18. A gene-expression signature as a predictor of survival in breast cancer.
    N Engl J Med. 2002 Dec 19;347(25):1999-2009 PMID: 12490681
  19. ArrayExpress--a public repository for microarray gene expression data at the EBI.
    Nucleic Acids Res. 2003 Jan 1;31(1):68-71 PMID: 12519949
  20. Gene expression predictors of breast cancer outcomes.
    Lancet. 2003 May 10;361(9369):1590-6 PMID: 12747878
  21. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
    Lancet. 2003 Aug 2;362(9381):362-9 PMID: 12907009
  22. A microarray platform comparison for neuroscience applications.
    J Neurosci Methods. 2004 Jan 15;132(1):57-68 PMID: 14687675
  23. Gene expression profiles of primary breast tumors maintained in distant metastases.
    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 PMID: 14665696
  24. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
    J Clin Oncol. 2004 Jun 15;22(12):2284-93 PMID: 15136595
  25. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
    J Clin Oncol. 2005 Feb 1;23(4):732-40 PMID: 15681518
Article Info
Journal
BMC genomics
Abbr.
BMC Genomics
ISSN
1471-2164
Published
2006-10-30
Epub
2006-00-30
Pages
278
Language
English
Region
England
NLM ID
100965258
PMCID
PMC1636049
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com